Versartis Inc. (NASDAQ:VSAR) saw an uptick in trading volume on Monday . 135,854 shares changed hands during mid-day trading, an increase of 58% from the previous session’s volume of 86,032 shares.The stock last traded at $13.09 and had previously closed at $12.91.

Several research firms have recently weighed in on VSAR. Zacks Investment Research downgraded shares of Versartis from a “buy” rating to a “hold” rating in a research note on Saturday, August 13th. Citigroup Inc. set a $23.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Thursday, August 11th. Canaccord Genuity set a $28.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Thursday, August 11th. Finally, Credit Suisse Group AG reissued a “sell” rating and issued a $9.00 price target on shares of Versartis in a research note on Friday, July 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $18.00.

The company has a 50-day moving average price of $11.38 and a 200 day moving average price of $9.38. The stock’s market cap is $386.69 million.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. On average, analysts predict that Versartis Inc. will post ($2.76) EPS for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.